Nimble Therapeutics announced today that it has spun out from F. Hoffman-La Roche as a standalone biotech company.

According to a release, Nimble Therapeutics will commercialize its proprietary chemical synthesis technology for drug discovery and development. The company, which hired the former Roche team that helped develop its chemical synthesis technology for drug discovery, will expand its current collaborations and develop new relationships in key therapeutic areas.

“As a fully independent company, Nimble Therapeutics will establish strategic partnerships with pharmaceutical companies to jointly develop unique drug candidates more efficiently across many therapeutic areas,” Nimble Therapeutics CEO Jigar Patel said in a statement.

The company, located at 500 S. Rosa Rd., also announced it has completed a Series A financing round, which was led by Telegraph Hill Partners.

Roche announced in 2018 that it was planning to close Roche Sequencing Solutions (formerly known as NimbleGen) in Madison.